PharmaCyte Biotech, Inc.
PMCB
$1.21
-$0.01-0.82%
NASDAQ
| 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -3.05M | -1.47M | 23.42M | 1.35M | -619.50K |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2.11M | 864.20K | -23.92M | -1.77M | 306.70K |
| Change in Net Operating Assets | 422.20K | -449.30K | 125.70K | 87.10K | 135.70K |
| Cash from Operations | -509.90K | -1.05M | -373.30K | -333.00K | -177.10K |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 0.00 | 0.00 | -7.00M | 0.00 | -5.00M |
| Cash from Investing | 0.00 | 0.00 | -7.00M | 0.00 | -5.00M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | 0.00 | 0.00 |
| Repurchase of Common Stock | -225.00K | -1.40M | -742.20K | -1.17M | -400.70K |
| Issuance of Preferred Stock | -- | -- | -- | 0.00 | 0.00 |
| Repurchase of Preferred Stock | -3.72M | -9.34M | -9.43M | -9.52M | -6.64M |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -3.95M | -10.74M | -10.17M | -10.70M | -7.04M |
| Foreign Exchange rate Adjustments | -1.20K | 100.00 | 200.00 | -400.00 | 1.10K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -4.46M | -11.80M | -17.54M | -11.03M | -12.21M |